TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03770481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led communication strategy
Description: Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
Study: NCT01679899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg bid orally for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: Gliclazide MR 60 or 120mg orally for 12 months
Study: NCT03096782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study: NCT03770481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led communication strategy
Description: Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led communication strategy
Description: Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
Study: NCT03096782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study: NCT01542879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WB-DW-MR scan
Description: WB-DW-MR scans will be obtained on a 3T PET-MR system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18-F-FDG PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18-F-FDG PET/MR scan
Study: NCT03096782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo cord blood transplant
Study: NCT03662750

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain Imaging
Description: The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans.
Study: NCT00612313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention cognitive behavioral therapy (CBT)
Description: After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
Study: NCT02927691

Intervention type: DEVICE
Group type: OTHER
Intervention: EMST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smTAP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smTAP
Study: NCT02497768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of nuts
Description: The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
Study: NCT03202316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05059015

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CERVICAL HPV
Description: A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SELF SAMPLING HPV
Description: A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SELF SAMPLING HPV
Description: A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
Study: NCT03843788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
Study: NCT03823651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric consult
Description: Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric consult
Description: Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/diet evaluation
Description: PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/diet evaluation
Description: PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Social Worker
Description: Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Social Worker
Description: Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
Study: NCT01464918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) using device, MASTER
Description: Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
Study: NCT02586701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Plus
Description: Supervised exercise program and home-based exercise program.
Study: NCT00687505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-1039
Description: Intravenous weekly administration
Study: NCT02839434

Intervention type: PROCEDURE
Intervention: Blood sample
Description: This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
Study: NCT00620230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-VAK694
Study: NCT01312116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: Internet-delivered cognitive behavior therapy, 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPDT
Description: Internet-delivered psychodynamic therapy, 8 weeks
Study: NCT01326780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2% JNJ 10229570-AAA
Description: 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.4% JNJ 10229570-AAA
Description: 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.6% JNJ 10229570-AAA
Description: 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Color matched cream vehicle, applied once daily to the face for 12 weeks
Study: NCT01176825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavior therapy (CBT)
Description: 14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
Study: NCT01668095

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04292158

Intervention type: DEVICE
Intervention: SomnoTouch
Description: The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis.

Intervention type: DEVICE
Intervention: MOX
Description: The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis.
Study: NCT03992105

Intervention type: OTHER
Group type: OTHER
Intervention: prospective cohort
Description: topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively
Study: NCT01455883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 mcg/day
Description: exenatide in DUROS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral glimepiride does-escalated,if tolerated, to 8 mg/day
Study: NCT03508089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocular fundus on patient with Multiple Sclerosis
Description: Ocular fundus on patient with Multiple Sclerosis

Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Fundus on voluntary person
Description: Ocular Fundus on voluntary person
Study: NCT01023126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy
Description: Group psychotherapy once a week, under a psychiatrist supervision
Study: NCT00600821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
Study: NCT03290508

Intervention type: DIAGNOSTIC_TEST
Intervention: Prolaris Testing
Description: Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
Study: NCT04140669

Intervention type: DEVICE
Intervention: Automated Myocardial Performance Index (MPI)
Description: Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
Study: NCT01124890

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: early percutaneous coronary intervention

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: late percutaneous coronary intervention
Study: NCT04307758

Intervention type: OTHER
Intervention: Muscle Strength Assesment-Make Test
Description: For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.

Intervention type: OTHER
Intervention: Muscle Strength Assesment-Break Test
Description: For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
Study: NCT04132349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate 5 mg
Description: Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
Study: NCT02517580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK7)
Study: NCT01625052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement and use of Baska mask
Description: use of Baska mask as component of standard general anaesthetic
Study: NCT03062488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: multi-modal analgesia with IV acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: single modal analgesia
Study: NCT03388073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry extract I
Description: Seabuckthorn berry proanthocyanidin extract 250 mg single dose
Study: NCT03891732

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI prostate
Description: plain biparametric MRI prostate
Study: NCT04166877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate in Parenteral Dosage Form
Description: IV bolus followed by continuous infusion for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: IV bolus followed by continuous infusion for 24 hours
Study: NCT04305184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0598
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
Study: NCT03388073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry Extract II
Description: Seabuckthorn berry proanthocyanidin extract 500 mg single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berry extract blend
Description: Seabuckthorn berry blend with other berry-based antioxidants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00030797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan 70 mg/m2
Description: Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan 240 mg/m2
Description: Irinotecan i.v. 240 mg/m2 day 1 and day 22
Study: NCT03882619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calligraphy
Description: Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
Study: NCT01014494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaprev
Description: Class III Medical Device
Study: NCT01696630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study: NCT03520491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
Study: NCT04305184

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.